profit from every $100 of sales.
$0$100
Sera Prognostics
$2.01+1.52% today
-31.9% in 1 year
1-year low $1.591-year high $3.69
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Sera Prognostics sold, what it kept, and what it did with the cash.
Sales went from $268,000 in 2022 to $81,000 in 2025, with -$31.9 million of profit last year.
SalesProfit
Sera Prognostics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sera Prognostics | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Sera Prognostics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | -0 | -0 | |
| -46 | -40 | -37 | -37 | |
| -43 | -35 | -32 | -31 | |
| -44 | -36 | -33 | -32 | |
| -1.43 | -1.16 | -0.99 | -0.67 | |
| 28.0% | 31.4% | -6.5% | -102.5% | |
| -17,034.3% | -13,013.4% | -47,577.9% | -45,066.7% | |
| -16,487.3% | -11,843.8% | -42,724.7% | -39,417.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 116 | 95 | 73 | 102 |
| Cash | 30 | 4 | 4 | 4 |
| Total debt | 3 | 2 | 1 | 2 |
| Total liabilities | 17 | 25 | 25 | 27 |
| 99 | 70 | 48 | 75 | |
| 31 | 31 | 33 | 48 | |
| -34.3% | -39.7% | -53.4% | -32.4% | |
| -44.7% | -51.7% | -68.8% | -42.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -35 | -27 | -14 | -26 | |
| 1 | 0 | 1 | 1 | |
| -35 | -27 | -15 | -26 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 5 | 7 | 5 |
Valuation
- –
- –
- –
- 1.4×
- 986.9×
- –
- –
- -33.0%
- -39.9%
- 0.0%
Profitability
- -102.5%
- -45,066.7%
- -39,417.3%
- -64,836.8%
- -52.2%
- -45.5%
- -41.0%
- -34.4%
- -52.2%
- 22,573.7%
Growth
- −32.9%
- –
- −72.3%
- –
- +11.6%
Financial health
- -0.1×
- 0.04
- 2.7%
- -12,204.7×
- 2.12
- 2.12
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 963
Bottom 2%of 908
Bottom 1%of 991
What analysts expect
- Average price target
- $5.00
- Range
- $5.00 – $5.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.17 | -0.16 | −6.3% |
| Mar 18, 2026 | -0.16 | -0.17 | +5.9% |
| Nov 13, 2025 | -0.16 | -0.19 | +15.8% |
| Aug 6, 2025 | -0.16 | -0.21 | +23.8% |
| May 7, 2025 | -0.20 | -0.24 | +16.7% |
| Mar 19, 2025 | -0.25 | -0.23 | −8.7% |
| Nov 6, 2024 | -0.24 | -0.22 | −9.1% |
| Aug 7, 2024 | -0.25 | -0.23 | −8.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
54No pass
Philip Fisher
29No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
26No pass
Questions about Sera Prognostics
Is Sera Prognostics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sera Prognostics AI analysis
What does Sera Prognostics do?
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. It is in Medical - Diagnostics & Research.
Does Sera Prognostics pay a dividend?
No. Sera Prognostics does not pay a dividend at the moment.
Is Sera Prognostics stock halal?
Questionable. Sera Prognostics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Sera Prognostics stock done over the past year?
Down 31.9% over the past twelve months, to $2.01. It traded between $1.59 and $3.69 and is 45.5% below its high.
Who are Sera Prognostics's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Sera Prognostics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.